MiNK Therapeutics, Inc. - Common Stock (INKT)

Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine.

MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026. The company also lau

MiNK (INKT) Q4 2025 Earnings Call Transcript

MiNK (INKT) Q1 2026 Earnings Call Transcript

MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management s

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

MiNK Therapeutics (INKT) Earnings Call Transcript

MiNK Therapeutics Q2 2025 earnings miss EPS estimates with a $1.06 loss per share, but cash runway extends to mid-2026. Clinical progress in cancer and GvHD offers future potential.

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.